We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Cells in Blood Manipulated and Sorted Via Ferrofluids

By LabMedica International staff writers
Posted on 16 Dec 2009
Technology that uses magnetizable liquids (ferrofluids) to rapidly manipulate and sort different cells in blood, could dramatically improve the speed and sensitivity of tests used to detect cancer biomarkers, blood disorders, viruses, and other diseases. More...
The new method does not require attaching biomarkers, or labels to the cells thus eliminating labor-intensive preparation or postprocessing.

Ferrofluids comprise magnetic nanoparticles suspended throughout a liquid carrier. A biocompatible ferrofluid--one with the right pH level and salinity so that human cells can survive in it for several hours—was developed together with a device that has integrated electrodes that generate a magnetic field pattern.

The magnetic field attracts the nanoparticles in the ferrofluid, effectively pushing and shuffling the much larger, nonmagnetic cells along specific channels. Depending on the frequency of the magnetic field applied different types of cells are manipulated and sorted according to their size, elasticity, and shape.

Being able to effectively sort and move cells with this technique could allow for much greater efficiency in disease detection. Many of today's tests require hours or even days to complete, because the concentration of diseased cells in a blood sample may be so low that it takes a long time for them to randomly bump into the sensors. For example, in early-stage cancer there could be one tumor cell for every billion healthy cells, making the cells extremely difficult to detect.

The new technology was developed by a team of scientists led by Hur Koser, associate professor at the Yale School of Engineering & Applied Science (New Haven, CT, USA) together with colleagues at the Deutsches Elektronen-Synchrotron (DESY; Hamburg, Germany) and University of Georgia (Athens, GA, USA). The findings were published in the December 7, 2009 online edition of the Proceedings of the National [U.S.] Academy of Sciences (PNAS).

Related Links:
Yale School of Engineering & Applied Science
Deutsches Elektronen-Synchrotron
University of Georgia


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
Multichem ID-B
New
Automatic Hematology Analyzer
LABAS F9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.